SCHEMBL7785352

SCHEMBL7785352

CSC(=N)NCCCC[C@@H](N)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 5/20 0.47
NOS1 P29475 5/20 0.47
NOS2 P35228 5/20 0.46
CYP2C19 P33261 1/20 0.46
THPO P40225 1/20 0.46
GSR P00390 1/20 0.46
OTC P00480 1/20 0.45
DPP7 Q9UHL4 1/20 0.42
ARG2 P78540 4/20 0.42
ARG1 P05089 3/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
TSHR P16473 1/20 0.41
GNAI3 P08754 1/20 0.41
GNAO1 P09471 1/20 0.41
GNAI1 P63096 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7984675 1.00 NOS3 (0.47) NOS3NOS1NOS2CYP2C19THPO
S-Methyl-D-Thiocitrulline SCHEMBL7787855 0.95 OTC (0.50) NOS3NOS1NOS2CYP2C19THPO
Thiocitrulline SCHEMBL8271436 0.95 OTC (0.50) NOS3NOS1NOS2CYP2C19THPO
Thiocitrulline SCHEMBL31698913 0.94 OTC (0.49) NOS3NOS1NOS2CYP2C19THPO
SCHEMBL7785336 0.84 GSR (0.43) NOS3NOS1NOS2GSROTC
SCHEMBL7788124 0.84 NOS1 (0.49) NOS3NOS1NOS2GSROTC
SCHEMBL7789549 0.84 GSR (0.43) NOS3NOS1NOS2GSROTC
SCHEMBL7791700 0.84 NOS1 (0.49) NOS3NOS1NOS2GSROTC
SCHEMBL19981422 0.83 NOS3 (0.49) NOS3NOS1NOS2CYP2C19THPO
SCHEMBL1387804 0.82 OTC (0.41) NOS3NOS1NOS2GSROTC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0723438-A1 SUBSTITUTED UREA AND ISOTHIOUREA DERIVATIVES AS NO SYNTHASE INHIBITORS THE WELLCOME FOUNDATION LIMITED (GB) 1996-07-31 EP claimed
WO-1995009619-A2 SUBSTITUTED UREA AND ISOTHIOUREA DERIVATIVES AS NO SYNTHASE INHIBITORS THE WELLCOME FOUNDATION LIMITED (GB) 1995-04-13 WO claimed
US-20010034342-A1 Substituted urea and isothiourea derivatives as no synthase inhibitors OPLINGER JEFFREY ALAN (US) 2001-10-25 US disclosed
US-6297276-B1 Substituted urea and isothiourea derivatives as no synthase inhibitors GLAXOSMITHKLINE 2001-10-02 US disclosed
US-6225305-B1 Substituted urea and isothiorea derivatives as no synthase inhibitors GLAXO WELLCOME INC. 2001-05-01 US disclosed
US-6090846-A ADMINISTERING S-ETHYL-N-((4-TRIFLUOROMETHYL)PHENYL)ISOTHIOUREA GLAXO WELLCOME INC. (US) 2000-07-18 US disclosed
EP-0723438-A1 SUBSTITUTED UREA AND ISOTHIOUREA DERIVATIVES AS NO SYNTHASE INHIBITORS THE WELLCOME FOUNDATION LIMITED (GB) 1996-07-31 EP disclosed
WO-1995009619-A2 SUBSTITUTED UREA AND ISOTHIOUREA DERIVATIVES AS NO SYNTHASE INHIBITORS THE WELLCOME FOUNDATION LIMITED (GB) 1995-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034342-A1 Substituted urea and isothiourea derivatives as no synthase inhibitors NOS1, NOS2, SLC14A1 NOS3 4/4885NOS1 1/4885NOS2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.